Wealthfront Advisers LLC Decreases Stake in Abbott Laboratories $ABT

Wealthfront Advisers LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 28.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,993 shares of the healthcare product maker’s stock after selling 45,803 shares during the quarter. Wealthfront Advisers LLC’s holdings in Abbott Laboratories were worth $12,114,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Freemont Management S.A. lifted its position in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after purchasing an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories during the 4th quarter worth about $116,580,000. Thrivent Financial for Lutherans grew its position in Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the period. Mn Services Vermogensbeheer B.V. raised its stake in shares of Abbott Laboratories by 2.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock valued at $84,163,000 after buying an additional 13,543 shares during the last quarter. Finally, Net Worth Advisory Group acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $1,366,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ABT has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Raymond James Financial decreased their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Oppenheimer lowered their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Leerink Partners cut their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Finally, Sanford C. Bernstein decreased their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $117.61.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 expectations with adjusted EPS of $1.31 versus $1.28 expected, showing better-than-expected profitability. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60, above its prior range, signaling confidence in earnings momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Revenue grew 13% year over year, supported by strong demand in medical devices, diagnostics, and emerging markets, which points to broad-based operating strength. Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Positive Sentiment: Heart-device demand and diagnostics growth, including a surge in sales tied to that segment, improved investor sentiment around Abbott’s longer-term growth profile. Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
• Neutral Sentiment: Abbott’s profit fell sharply from a year ago on a GAAP basis, but the decline was offset by stronger sales and guidance, making this more of a quality-over-headline-results story. Abbott Laboratories Sales Rise on Diagnostics Growth
• Negative Sentiment: Broader market and tech sell-off headlines may have slightly tempered enthusiasm, but they were not the main driver of ABT’s move. Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off

Abbott Laboratories Stock Up 10.7%

ABT opened at $98.81 on Friday. The company has a market cap of $172.11 billion, a PE ratio of 27.68, a price-to-earnings-growth ratio of 1.54 and a beta of 0.61. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a 50-day moving average price of $89.56 and a 200 day moving average price of $102.18. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.